Ad Astra Awards
Ad Astra Journal
Science library
White book
University rankings
Who's who
Theses and dissertations
Ad Astra association
Press releases
Funding opportunities
>> Românã

Emmanuelle Tavernier, Carmen Aanei, Françoise Solly, Pascale Flandrin-Gresta , Lydia Campos , Denis Guyotat . CXCR4: a new therapeutic target of the leukaemic cell?. Bulletin du cancer, 2014.

Abstract: CXCR4, receptor of the chemokine SDF-1 (stromal cell-derived factor 1) plays a major role in the normal hematopoiesis but also in the biology of the leukaemic cell. This receptor is expressed on the surface of blasts and is a key molecule in "the anchoring" of the leukaemic stem cell (LSC) within the bone marrow niche. The interactions of the LSC with the bone marrow microenvironment promote survival signals and drug resistance. Recent flow cytometry analyses reported that CXCR4 expression levels have a major prognostic impact in acute myeloid leukaemia (AML). CXCR4 expression is associated with poor prognosis and can be useful to stratify patients, according to their phenotype, in order to establish risk-adapted strategies. Newly diagnosed AML are now routinely stratified according to molecular markers which guide prognosis and treatment. Many leukaemia are composed of multiples subclones with differential susceptibility to treatment and specific targeted therapies are missing. Despite therapeutic improvements for the treatment of AML, long term survival remains poor. Targeting CXCR4 is a novel promising approach of therapy. CXCR4 antagonists are used in combination with chemotherapy in preclinical and clinical studies. This review summarises our current knowledge regarding the key role of CXCR4 in AML and discusses how targeting this pathway could provide an interesting approach to eradicate the LSC.

Keywords: leukaemic stem cell, acute myeloid leukaemia, CXCR4

Posted by Carmen-Mariana AANEI


© Ad Astra 2001-2013